Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape. H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively. Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Influenza A Virus, H5N1 Subtype Infections - Overview Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development Akshaya Bio Inc Altimmune Inc Antigen Express Inc Aphios Corp BiondVax Pharmaceuticals Ltd CEL-SCI Corp Cocrystal Pharma Inc Curevac AG Gemmus Pharma Inc GlaxoSmithKline Plc Hemispherx Biopharma Inc iBio Inc Inovio Pharmaceuticals Inc Johnson & Johnson Kineta Inc Lakewood-Amedex Inc Medicago Inc Medigen Vaccine Biologics Corp Microbiotix Inc NanoBio Corp Nanotherapeutics Inc NanoViricides Inc OPKO Health Inc PaxVax Inc PeptiDream Inc Shionogi & Co Ltd Takeda Pharmaceutical Company Ltd TechnoVax Inc Vaxart Inc Vaxine Pty Ltd Visterra Inc Influenza A Virus, H5N1 Subtype Infections - Drug Profiles A-06 - Drug Profile Product Description Mechanism Of Action R&D Progress AE-AI vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Alferon LDO - Drug Profile Product Description Mechanism Of Action R&D Progress APP-0205 - Drug Profile Product Description Mechanism Of Action R&D Progress APP-309 - Drug Profile Product Description Mechanism Of Action R&D Progress AT-301 - Drug Profile Product Description Mechanism Of Action R&D Progress beraprost sodium - Drug Profile Product Description Mechanism Of Action R&D Progress CC-42344 - Drug Profile Product Description Mechanism Of Action R&D Progress CEL-1000 - Drug Profile Product Description Mechanism Of Action R&D Progress CHOS-05 - Drug Profile Product Description Mechanism Of Action R&D Progress DPC-005 - Drug Profile Product Description Mechanism Of Action R&D Progress Gamma-Flu - Drug Profile Product Description Mechanism Of Action R&D Progress GP-1002 - Drug Profile Product Description Mechanism Of Action R&D Progress GP-1681 - Drug Profile Product Description Mechanism Of Action R&D Progress GREFLU/VIE - Drug Profile Product Description Mechanism Of Action R&D Progress HAI-05 - Drug Profile Product Description Mechanism Of Action R&D Progress HB-36.6 - Drug Profile Product Description Mechanism Of Action R&D Progress Influ-nRNA - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] (split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H5N1] vaccine 2 - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H5N1 + A/H1N1] (trivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress INO-3510 - Drug Profile Product Description Mechanism Of Action R&D Progress KIN-1148 - Drug Profile Product Description Mechanism Of Action R&D Progress Lalistat - Drug Profile Product Description Mechanism Of Action R&D Progress M-001 - Drug Profile Product Description Mechanism Of Action R&D Progress MBX-2329 - Drug Profile Product Description Mechanism Of Action R&D Progress MBX-2546 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile Product Description Mechanism Of Action R&D Progress MV-4 - Drug Profile Product Description Mechanism Of Action R&D Progress Nasovax - Drug Profile Product Description Mechanism Of Action R&D Progress NVINF-1 - Drug Profile Product Description Mechanism Of Action R&D Progress NVINF-2 - Drug Profile Product Description Mechanism Of Action R&D Progress PD-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides for Influenza Infections - Drug Profile Product Description Mechanism Of Action R&D Progress pimodivir hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress PNSIA-28 - Drug Profile Product Description Mechanism Of Action R&D Progress PNSIA-49 - Drug Profile Product Description Mechanism Of Action R&D Progress PXVX-0103 - Drug Profile Product Description Mechanism Of Action R&D Progress S-033188 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate Sirtuin for Influenza - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides for Viral Infections - Drug Profile Product Description Mechanism Of Action R&D Progress TVX-003 - Drug Profile Product Description Mechanism Of Action R&D Progress VGX-3400X - Drug Profile Product Description Mechanism Of Action R&D Progress VH-244 - Drug Profile Product Description Mechanism Of Action R&D Progress VIS-410 - Drug Profile Product Description Mechanism Of Action R&D Progress Influenza A Virus, H5N1 Subtype Infections - Dormant Projects Influenza A Virus, H5N1 Subtype Infections - Discontinued Products Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones Featured News & Press Releases Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C. Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company's Universal Flu Vaccine Jan 21, 2014: BiondVax's universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8 Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Hemispherx Biopharma Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by iBio Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoBio Corp, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Nanotherapeutics Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by PaxVax Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Visterra Inc, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..3), H2 2017 Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
